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AbstrAct
Objective To assess the effectiveness of sitagliptin 
compared to sulfonylureas as add-on to metformin in 
adults with type 2 diabetes mellitus from both randomised 
controlled trials (RCTs) and ‘real-world’ non-randomised 
studies.
Methods and analyses We conducted a systematic 
review of EMBASE, MEDLINE, CENTRAL and grey 
literature for RCTs and non-randomised studies. We 
reported outcomes relating to change in HbA1c, fasting 
glucose, weight, blood pressure and lipids from baseline 
and need for treatment change. No study investigating 
macrovascular and microvascular diabetes complications 
was found. Meta-analysis was used where studies were 
sufficiently homogenous.
results Seven RCTs and five non-randomised studies 
were eligible for inclusion from 1335 articles retrieved. 
Meta-analysis of three homogenous RCTs revealed a 
statistically significant decrease in weight with sitagliptin 
when compared to sulfonylureas (weighted mean 
difference (WMD) −2.05 kg; 95% CI −2.38 to −1.71); 
however, a similar change from baseline in HbA1c (WMD 
0.05; 95% CI −0.03 to 0.12), fasting glucose (WMD 0.11; 
95% CI −0.08 to –0.29), blood pressure, lipids and the 
proportion achieving HbA1c <7% by study end (OR 0.98; 
95% CI 0.85 to 1.13) was observed. Non-randomised 
studies identified consisted of four prospective and one 
retrospective cohort study. Three of these five studies were 
of moderate/high quality, and results though less precise 
suggested similar real-world comparative glycaemic and 
weight effectiveness for both treatments. Data from two 
cohort studies suggested that treatment change (HR 0.65; 
95% CI 0.57 to 0.73) and insulin initiation (HR 0.76; 95% CI 
0.65 to 0.90) were less likely among those prescribed 
sitagliptin; however, inadequate reporting of HbA1c at time 
of treatment change made interpreting results challenging.
conclusion Sitagliptin users experienced modest weight 
loss compared to gain with sulfonylureas; however, this 
difference was around 2 kg, which may not be of major 
clinical significance for most individuals. Similar change 
was observed across most other effectiveness outcomes 
reported. Further studies are needed to address longer-
term effectiveness outcomes for sitagliptin compared to 
sulfonylureas as add-on to metformin.
PrOsPErO registration number CRD42016033983.
IntrOductIOn
Management of patients with type 2 diabetes 
mellitus (T2DM) is complex and often 
requires multiple pharmacological treat-
ments to achieve adequate control of the 
disease.1 2 Most clinical guidelines recom-
mend metformin as initial monotherapy; 
however, there is no consensus on second-
line treatment.1–4 This is further complicated 
by the increasing number of pharmacological 
treatments options now available. Dipepti-
dyl-peptidase-4 (DPP-4) inhibitors and sulfo-
nylureas represent two of the largest classes 
of therapy prescribed worldwide.5 6 Sitagliptin 
has been the most extensively prescribed 
DPP-4 inhibitor in the UK and USA,7 while 
alongside metformin, sulfonylureas such as 
gliclazide are the most widely prescribed oral 
antidiabetic agent for T2DM.5 Sitagliptin 
slows the inactivation of incretin hormones 
(glucagon-like-peptide-1 and glucose insu-
linotropic peptides), which in turn increase 
insulin synthesis and release and suppress 
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Research
strengths and limitations of this study
 ► We provide a comprehensive overview examining a 
wide range of effectiveness outcomes for sitagliptin 
versus sulfonylureas as add-on to metformin.
 ► We assess and report evidence from both 
randomised clinical trials and ‘real-world’ non-
randomised studies.
 ► We have undertaken and presented meta-analysis 
where methodologically appropriate.
 ► We have focused on effectiveness issues only in 
this review as safety has been evaluated in depth 
elsewhere; however, we have summarised the 
safety literature in our introduction.
 ► We have focused on sitagliptin only as this is the 
most widely prescribed dipeptidyl-peptidase-4 
inhibitor in the UK.
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glucagon release.8 Sulfonylureas, however, work solely 
through increasing insulin secretion via direct stimula-
tion of β-cells in the pancreas.8 Clinicians often have to 
choose between prescribing sitagliptin or a sulfonylurea 
as potential options to add-on in patients with T2DM 
inadequately controlled on metformin.5
Clinical guidance from the American Association of 
Clinical Endocrinologists now recommends sitagliptin 
usage over sulfonylureas for second-line treatment9; 
however, most other major international guidelines such 
as those from the UK National Institute of Heath and 
Care Excellence, American Diabetes Association, Euro-
pean Association for study of Diabetes and International 
Diabetes Federation do not significantly discriminate 
between treatments and advocate that either may be 
selected as potential options to add-on, having accounted 
for patient preferences and medication safety.1–4 Medica-
tion safety takes priority across Asian clinical guidelines 
as well, which tend to be individualised across most coun-
tries10; however, studies have shown increasing usage of 
both treatments particularly in Eastern Asian countries as 
well.6
From a safety perspective, both sulfonylureas and 
sitagliptin have been studied in considerable depth. To 
summarise, a several-fold higher risk of hypoglycaemia 
has been well established with sulfonylureas across adult 
and several vulnerable population groups such as older 
individuals.11–14 An increased risk of pancreatitis with 
sitagliptin has also been reported,15 though absolute risk 
appears low, while conflicting evidence regarding a wors-
ening of heart failure in patients prescribed sitagliptin 
has been signalled.8 16
Though safety of both treatments has been well evalu-
ated, less has been characterised about the comparative 
effectiveness of sitagliptin compared to sulfonylureas 
from both randomised controlled trials (RCTs) and 
non-randomised studies using ‘real-world’ data.
Several randomised placebo controlled trials have been 
conducted on both sitagliptin and sulfonylureas17–20; 
however, these do not facilitate direct comparison 
between the two. We carried out a systematic review 
to collate and analyse evidence from both RCTs and 
non-randomised studies to ascertain the effectiveness of 
sitagliptin compared to sulfonylureas in patients inade-
quately controlled on metformin. We examined a wide 
range of clinical effectiveness outcomes for which data 
have been reported.
MEthOds
We conducted this systematic review in accordance with 
a prespecified published protocol.21 We have reported 
our findings in order to comply with both the PRISMA 
(Preferred Reporting Items for Systematic Reviews and 
Meta Analyses) statement and MOOSE (Meta-Anal-
yses and Systematic Reviews of Observational Studies) 
reporting guidelines.22 23
Eligibility criteria
A study was eligible if it was an RCT or non-randomised 
study conducted postmarketing authorisation comparing 
sitagliptin with sulfonylureas (gliclazide, glipizide, gliben-
clamide, tolbutamide, chlorpropamide, glimepiride) in 
adults with T2DM inadequately controlled on metformin. 
We required that all studies have a minimum of 1-month 
patient follow-up after initiation with sitagliptin or sulfo-
nylurea for outcomes (however, a minimum of 3 months 
was required for reported changes in HbA1c).
search strategy and study selection
Eligible studies written in English were identified using 
electronic searches for RCTs, non-randomised observa-
tional studies and conference abstracts using MEDLINE, 
the Cochrane Central Register of Controlled Trials 
(CENTRAL) from inception to 1 June 2016 and EMBASE 
(1 January 1980 to 1 June 2016). Search strategies were 
developed for individual databases and reviewed by an 
information specialist to ensure rigour (online supple-
mentary methods 1a–2c). Additional studies and grey 
literature were retrieved by screening references of 
retrieved studies and by searching International Phar-
macy Abstracts, conference proceedings on Scopus and 
the WHO international clinical trial registry. We also 
contacted authors and manufacturers directly in cases 
where data were not available in the public domain; 
however, no additional data were made available.
One reviewer (MS) performed the full search strategy, 
removed duplicates and selected the articles. A second 
reviewer (NB) independently analysed these selections 
for eligibility of inclusion. Studies were screened based on 
title and abstract initially, following which full texts were 
obtained and assessed for inclusion. All records identi-
fied in searches were managed and stored in a reference 
management software (EndNote X7, Thomson Reuters, 
New York, USA).
data extraction
All data were independently extracted by two reviewers 
(MS and NB) into standardised electronic forms. Data 
extracted included study details, participant details and 
intervention details (drug name, dose, frequency). 
Reported intention-to-treat analysis results were used 
where possible. Outcomes examined compared sitagliptin 
and sulfonylurea for change from baseline in HbA1c 
(%), fasting plasma glucose (mmol/l), weight (kg), body 
mass index (BMI) (kg/m2), systolic and diastolic blood 
pressure (mm Hg), total cholesterol (mmol/mol) and 
triglycerides (mmol/mol) and the number of individ-
uals achieving HbA1C at study end of <7% and <6.5%. 
In addition, all data on longer-term outcomes involving 
over 2 years of patient follow-up where reported were 
also extracted. This included data examining the risk 
of needing treatment change or insulin initiation after 
commencement of sitagliptin compared to sulfonylureas. 
We also proposed to extract data on longer-term outcomes 
examining risk of macrovascular and microvascular 
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complications of diabetes; however, no such data were 
retrieved. All disagreements between reviewers were 
resolved by consensus or discussion with a third (IN) and 
fourth reviewer (IP) where needed.
Quality assessment
The Cochrane Collaborations Risk of Bias Tool was used 
to assess heterogeneity and quality for the RCTs. All six 
domains in the risk of bias tool were assessed: random 
sequence generation, allocation concealment, blinding, 
incomplete outcome data and selective outcome 
reporting. Each domain was graded as (a) low bias, (b) 
unclear bias or (c) high bias.24
The methodological quality of non-randomised studies 
included was assessed using the Newcastle-Ottawa Quality 
Assessment Scale.25 This scale consists of a ‘star-rating 
system’ in which a study is judged on three broad domains: 
the selection of the study groups, the comparability of the 
groups and the ascertainment of either the exposure or 
outcome of interest for case-control or cohort studies, 
respectively.25
All study assessments were carried out independently 
by two reviewers and checked for agreement. Differences 
were resolved through consensus or in consultation with 
a third (IN) and fourth reviewer (IP).
data analysis
Mean differences (MDs) were calculated for continuous 
outcomes and ORs or HRs for dichotomous outcomes 
where possible. Adjusted data (adjusted OR or HR 
with 95% CI) from non-randomised studies were used 
where available. We planned to conduct meta-analysis if 
included articles were sufficiently homogenous and of 
high quality. However, given the wide range of research 
methods identified, significant variation in duration of 
follow-up across studies and overlapping patient popula-
tions in some studies, a meta-analysis across all studies was 
not deemed appropriate. Nonetheless, forest plots were 
constructed for comparison and an overall descriptive 
analysis was undertaken examining each outcome across 
the studies where reported with a comprehensive account 
of study quality.
We did undertake meta-analysis for outcomes where 
two or more studies were available of a sufficiently 
homogenous standard. Data synthesis was undertaken 
using a fixed-effects model (Mantel-Haenszel method) 
unless our assessment of study qualities determined that a 
fixed-effects model was unsuitable or significant hetero-
geneity was evident.26 Heterogeneity was assessed using 
the I2 statistic, with an I2 statistic greater than 50% consid-
ered indicative of significant heterogeneity and necessi-
tating use of a random-effects model (Dersimonian-Laird 
method) for meta-analysis.24 27
Sensitivity analysis undertaken to explore impact of 
duration of follow-up on meta-analysis results did not 
alter findings. All analysis was undertaken using STATA 
statistical software package (version 13).
rEsults
search results and study characteristics
In total, 12 studies were eligible for inclusion (figure 1) with 
a list of excluded studies following full text review in the 
online supplementary table S1. Included studies consisted 
of seven RCTs28–34 and five non-randomised (table 1).35–39 
Among the RCTs, four studies used glimepiride exclu-
sively as the sulfonylurea comparator,28–30 34 two studies 
exclusively used glipizide,32 33 while one study used glib-
enclamide.31 Among the non-randomised studies, use of 
various sulfonylureas were permitted. Duration of patient 
follow-up in the RCT studies ranged from 1 month for 
the shortest30 to 24 months for the longest studies.28 33 
Duration of patient follow-up was, in general, longer in 
the non-randomised studies ranging from 3 months in 
the shortest prospective cohort study38 to 72 months in 
the longest.36 Four of the seven RCT studies required 
patients to be on metformin at a dose of ≥1500 mg at 
baseline,28 29 32 33 while this was not required for any of the 
non-randomised studies. Further details on study exclu-
sion criteria can be found in online supplementary table 
S2.
The characteristics of participants across the studies 
are summarised in table 2. The study population ranged 
from 34 individuals in the smallest RCT30 to 1172 in the 
largest.33 Non-randomised study sizes ranged from 69 
participants to 20 529 individuals in the largest cohort 
study.36 37 The mean age of participants ranged from 54.3 
years to 59.6 years in the RCTs and 46.9 years to 64.2 years 
in the non-randomised studies. The mean baseline HbA1c 
ranged from 7.0% to 8.3% in the RCT, while it ranged 
from 7.5% to 8.7% across the non-randomised studies. 
Mean weight at baseline ranged from 80.6 kg to 91.8 kg 
in the RCTs, while it ranged from 63.8 kg to 74.5 kg in 
the non-randomised studies; however, it was often poorly 
reported.
Quality assessment
Risk of bias assessment for RCTs
Out of seven RCTs, three studies were judged to be at 
high risk of bias in one of the seven domains examined 
as shown in online supplementary table S3. A lack of 
blinding of participants and personnel put both Srivas-
tava et al and Koren et al at high risk of bias.31 34 Addi-
tionally, Koren et al was also deemed to be at high risk 
of selection bias due to the absence of adequate rando-
misation of participants.31 Kim et al was at high risk of 
reporting bias as all outcomes, for example, change in 
HbA1c were reported in absolute terms without adjust-
ment (despite imbalance in gender and baseline fasting 
plasma glucose after randomisation) and no comparative 
analysis examining both treatments was undertaken.30 In 
Kim et al, it was unclear whether sequence generation for 
randomisation was inadequate or baseline imbalances 
were simply due to the small sample size for the study of 
34. However, this lack of adjustment in analysis meant any 
results presented in Kim et al could not be used for our 
comparative analysis. Risk of other bias was also high for 
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Figure 1 PRISMA flow diagram: study identification, selection and exclusions. *Monthly automated alerts from 01/11/15 to 
01/06/16 consisting of updates to the search strategy identified additional articles in Embase, Medline and CENTRAL that have 
been included in the flow diagram above. However, no eligible studies for inclusion were obtained through these updates 
Srivastava et al due to a lack of information on baseline 
characteristics of study participants, which made the final 
study results challenging to interpret.34
Assessment of study quality of non-randomised observational 
studies using Newcastle-Ottawa Scale
Based on use of the Newcastle-Ottawa Scale described 
earlier, two of the five non-randomised studies were 
deemed to be of low quality as shown in online supple-
mentary table S4. Suraj et al achieved a low-quality 
rating as it did not meet the standard expected for 
cohort comparability mainly due to a failure to adjust 
for important confounders such as age, sex, baseline 
HbA1c, weight and metformin dose in the final analysis.38 
Derosa et al achieved a low-quality rating as they had a 
strict cohort study exclusion criteria excluding more ill 
diabetic patients, and though they matched for age, sex 
and diabetes duration, they failed to adjust for other 
potential relevant confounders such as socioeconomic 
status, comorbidities, among others. Derosa et al also had 
significant loss to follow-up and failed to describe it with 
sufficient clarity or evaluate whether this may have biased 
results.35 Further details on methodological approaches 
used to control confounding in each of the five non-ran-




Seven studies in total reported glycaemic change 
(figure 2A). We performed meta-analysis for three of 
these RCTs because they were of high quality and 
exceeded 6 months in duration. A fourth study, led by 
Nauck et al, could not be included for meta-analysis, as 
group.bmj.com on November 9, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5Sharma M, et al. BMJ Open 2017;7:e017260. doi:10.1136/bmjopen-2017-017260
Open Access
Table 1 Characteristics of the included studies
Study Type Sita dose Sulf dose Duration* Inclusion criteria
Primary 
outcome
Ahrén et al†28 RCT 100 mg Glim 2–4 mg 24 Aged ≥18 years and T2DM and 
baseline HbA1c ≥7.0% and 
≤10.0% and prescribed 
metformin ≥1500 mg or maximum 
tolerated dose, BMI 20–45 kg/m2; 
creatinine clearance >60 mL/min; 
normal thyroid-stimulating hormone 




Arechavaleta et al29 RCT 100 mg Glim 1–6 mg 7.5 Aged ≥18 years with T2DM and 
baseline HbA1c ≥6.5% and 





Kim et al30 RCT 100 mg Glim 2 mg 1 Aged 18–80 years and T2DM 
for <10 years baseline HbA1c 
≥7.0% and ≤10.0% prescribed 




Koren et al31 RCT 100 mg Glib 5 mg 3 Aged 18–75 years and T2DM 







Nauck et al32 RCT 100 mg Glip 5–20 mg 12 Aged 18–78 years and T2DM 
and baseline HbA1c ≥6.5% and 





Seck et al‡33 RCT 100 mg Glip 5–20 mg 24 Aged 18–78 years and T2DM 
and baseline HbA1c ≥6.5% and 





Srivastava et al34 RCT 50–
200 mg
Glim 1–4 mg 4.5 Aged ≥18 years with T2DM and 
baseline HbA1c ≥7.0% and 




Derosa et al35 Prosp. Cohort 100 mg Var§ 60 Aged >18 years with T2DM and 
baseline HbA1c ≥8.0%, prescribed 




Inzucchi et al36 Retro. Cohort Var Var§ 72 Aged ≥18 years, initiated therapy 
with metformin in the 12 months 





Lee et al37 Prosp. Cohort 100 mg Var§ 6 Aged ≥18 years with T2DM with a 





Suraj et al38 Prosp. Cohort 100 mg Var§ 3 Aged 18–70 years with T2DM 





Valensi et al39 Prosp. Cohort 100 mg Var§ 36 Aged ≥18 years and prescribed 
metformin with inadequately 






*Duration reported in months.
†Only sitagliptin and sulfonylurea RCT arms considered.
‡Seck et al is an extended follow-up study of Nauck et al; only Seck et al was included for meta-analysis.
§Use of any sulfonylurea drug was permitted. In Suraj et al, 5 mg glibenclamide, 1 mg glimepiride or 60 mg gliclazide were permitted only.
BMI, body mass index; Glib, glibenclamide; Glim, glimepiride; Glip, glipizide; HbA1c, haemoglobin A1c; Prosp, prospective; RCT, randomised 
controlled trial; Retro, retrospective; Sita, sitagliptin; Sulf, sulfonylureas; T2DM, type 2 diabetes mellitus.
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Seck et al was an extended follow-up of this study and this 
would have led to double counting of patients. Meta-anal-
ysis showed that, compared to sulfonylureas, treatment 
with sitagliptin produced a similar glycaemic change, 
as measured by reductions in HbA1c from baseline: 
(weighted mean difference (WMD) in HbA1c 0.05%; 
95% CI −0.03% to 0.12%; I2=0%)) (graph in HbA1c units 
of mmol/mol is included in online supplementary figure 
S1). The odds of achieving a HbA1c of <7% by study end 
was also meta-analysed across these three RCTs, and no 
significant difference was observed between sitagliptin 
and sulfonylureas (OR 0.98 95%; CI 0.85 to 1.13, I2=0%) 
(figure 2D). Only in the shorter 4.5-month RCT study led 
by Srivastava, not included in meta-analysis, were sulfony-
lureas shown to be superior (mean difference (MD) in 
HbA1c 0.54%; 95% CI 0.43% to 0.64%).
Glycaemic change was also reported in the observa-
tional study led by Suraj et al (MD 0.49%; 95% CI 0.19% to 
0.79%) where a significantly greater reduction in HbA1c 
was observed with sulfonylureas (figure 2A). Derosa et al 
reported change from baseline in HbA1c after 5 years in a 
prospective cohort study; however, they did not undertake 
any formal analysis to adjust for relevant confounders, 
which made results difficult to interpret, and we have not 
presented them.
Weight change
Meta-analysis of the three RCTs that could be pooled 
showed statistically significant reduction in weight 
with sitagliptin from baseline compared to sulfony-
lureas (WMD −2.05 kg; 95% CI −2.38 to −1.71 kg; I2=0%) 
(figure 2B). This equated to a modest weight increase of 
approximately 1 kg with sulfonylureas and loss of 1 kg with 
sitagliptin. Treatment with sitagliptin also showed signifi-
cant reduction in weight in the remaining RCTs as shown 
in figure 2B. The greatest comparative weight reduction 
was observed in the 12-month RCT led by Nauck et al (MD 
−2.60 kg; 95% CI −3.31 to −1.89 kg).
The prospective cohort study led by Suraj et al also 
revealed a similar weight reduction as the RCTs38; 
however, the cohort study led by Valensi et al did not find 
this reduction to be significant with a longer 36-month 
follow-up (figure 2B).39
Changes in body mass index were also reported in a 
small number of studies, and as results, necessarily, mirror 
weight change, they have been included in appendix for 
reference (online supplementary figure S2).
Fasting plasma glucose
Meta-analysis of the three RCTs showed that, compared to 
sulfonylureas, treatment with sitagliptin produced similar 
change in fasting plasma glucose (mmol/l) from base-
line (WMD 0.11 mmol/L 95%; CI −0.08 to 0.29 mmol/L; 
I2=0%) (figure 2C). Of the remaining RCTs, only the 
shorter 4.5-month RCT study led by Srivastava et al 
demonstrated a more significant reduction in fasting 
plasma glucose with sulfonylureas (MD 0.81 mmol/l %; 
95% CI 0.70 to 0.92 mmol/L).
The observational study led by Suraj et al also demon-
strated a more significant reduction in fasting plasma 
glucose with sulfonylureas compared to sitagliptin (MD 
1.02 mmol/L; 95% CI 0.52 to 1.52 mmol/L).38
Blood pressure and lipid changes
Two RCTs reported no significant difference between 
sitagliptin and sulfonylureas for change in systolic and 
diastolic blood pressure, level of triglycerides and choles-
terol between study end and baseline (figure 3A–D).
In the RCT led by Ahren et al, a clinically insignificant 
but statistically significant reduction in total cholesterol 
was observed with sitagliptin compared to sulfonylureas 
(MD −0.16 mmol/mol; 95% CI −0.29 to −0.03 mmol/
mol).28
Longer-term outcomes
Two non-randomised studies reported outcomes 
from longer follow-up of patients not reported in any 
RCTs retrieved. The 36-month cohort study led by 
Valensi et al explored the risk of needing treatment 
change after add-on of sitagliptin compared to sulfony-
lureas (figure 3E).39 They found that the adjusted risk of 
needing treatment change was lower with sitagliptin (HR 
0.65; 95% CI 0.57 to 0.73).
The 72-month cohort study led by Inzucchi et al demon-
strated that individuals prescribed sitagliptin had a lower 
risk for initiating insulin during follow-up after relevant 
adjustment (HR 0.76; 95% CI 0.65 to 0.90) (figure 3F).36
dIscussIOn
In this systematic review, the meta-analysis conducted 
using three RCTs in which follow-up was greater than 6 
months demonstrated similar glycaemic improvement 
after add-on of sitagliptin compared to sulfonylureas 
in individuals inadequately controlled on metformin. 
Statistically significant reduction in weight of approxi-
mately 2 kg was observed with sitagliptin when compared 
to sulfonylureas driven by modest weight increase with 
sulfonylureas and modest decrease with sitagliptin. This 
may not be of clinical significance for most individ-
uals other than those at more extremes of weight, for 
example, frail elderly patients or those struggling to lose 
weight. Outcome reporting for change in blood pres-
sure and lipids from baseline was low, and meta-analysis 
was not possible, although data from two RCTs did not 
show any clinically meaningful difference between both 
add-on treatments. Two cohort studies reported longer-
term outcomes, relating to time before a treatment 
change or insulin initiation was needed. In both of these 
high-quality non-randomised studies, results suggested 
that fewer individuals prescribed sitagliptin than sulfo-
nylureas needed treatment change at 36-month and 
72-month follow-ups, respectively.
Meta-analysis of high-quality homogenous RCTs 
represents the highest source of evidence,40 and we identi-
fied three homogenous RCTs for meta-analysis. However, 
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the RCT inclusion criterias may have led to exclusion of 
important population subgroups frequently seen in clin-
ical practice decreasing external validity of the findings 
from the meta-analysis alone. For example, Arechavaleta et 
al excluded individuals with a baseline HbA1c >9%,29 and 
Seck et al excluded individuals >78 years of age.33 Drug 
utilisation studies have shown that such criteria alone can 
exclude close to 50% of individuals seen in real-world 
clinical practice.41 Therefore, by assessing and reporting 
on the quality of the remaining clinical trials that could 
not be meta-analysed (some of which had more prag-
matic inclusion criteria31) and including non-randomised 
studies that provide insight into effectiveness in actual 
clinical practice and longer-term outcomes, we believe 
this study was made more informative.
Glycaemic control achieved with sitagliptin or sulfony-
lureas in patients inadequately controlled on metformin 
was similar in our meta-analysis. Synergistic improvement 
in glycaemic effectiveness has been reported when sita-
gliptin and metformin are used together; however,42 our 
study has shown that the glycaemic reduction results 
are similar to that achieved when metformin and sulfo-
nylureas are used together. One RCT34 and cohort 
study reported significant reductions in HbA1c and 
fasting glucose with sulfonylureas compared to sita-
gliptin; however, these were both of 4.5 months in dura-
tion only.38 This peak in sulfonylurea glycaemic efficacy 
within the first 6 months of treatment has been previously 
described.43 44 For all studies of greater than 6-month 
duration, we found that glycaemic benefit with sitagliptin 
and sulfonylurea was comparable in line with guidance 
from major international bodies.1–4 9
Statistically significant weight loss with sitagliptin 
compared to sulfonylurea of approximately 2 kg was 
evident in our meta-analysis and also across all RCTs 
and non-randomised studies reported up to 2 years in 
duration. This difference was driven by modest weight 
decrease with sitagliptin and increase with sulfonylureas. 
Sitagliptin is often described as having only a weight 
neutral effect45–47; however, when compared directly 
with sulfonylureas, a small reduction in weight is evident. 
This comparative reduction is unlikely to be clinically 
significant for most individuals other than those at more 
extremes of weight or those struggling to lose weight.
Longer-term outcomes with follow-up greater 
than 2 years were reported in two cohort studies 
only.36 39 The risk of requiring a change in treatment or 
initiating insulin was found to be lower with sitagliptin, 
suggesting that sitagliptin patients are less likely to need 
treatment change over longer follow-up. However, deci-
sions to change treatment or initiate insulin are based on 
clinician decisions, which can be subjective and hence 
vary. Furthermore, treatment inertia is a well-established 
problem in care of individuals with type 2 diabetes.48 
Without data on glycaemic control at the time of treat-
ment change, we cannot fully assess whether clinicians 
changed treatment appropriately, making this finding 
challenging to interpret.
Only 2 RCTs reported data on markers of cardiovascular 
disease and these did not show any clinically significant 
change being achieved in blood pressure or lipids through 
being prescribed sitagliptin or sulfonylureas as add-on to 
metformin. Cardiovascular outcome studies comparing 
sitagliptin to placebo have also been conducted recently49; 
however, direct comparisons between a DPP-4 inhibitor 
and sulfonylurea will not emerge until 2019 on comple-
tion of the CAROLINA study.50 This study will focus on 
use of linagliptin rather than sitagliptin, which raises 
a challenge as recent RCT results for different DPP-4 
inhibitors were conflicting, raising the possibility that 
different DPP-4 inhibitors may exhibit different cardio-
vascular risks.49 51 52 Equally, the effect of sulfonylureas on 
cardiovascular disease is still poorly understood despite 
many years of usage.53 54 Studies have reported increased 
mortality from cardiovascular disease with use of sulfony-
lureas particularly tolbutamide and chlorpropamide43 55; 
however, results from more recent RCTs with newer sulfo-
nylureas like gliclazide are more reassuring.43 56 Further 
research is needed.
No RCTs or non-randomised studies reported longer-
term data on the risk of complications of diabetes such 
as retinopathy, neuropathy and nephropathy despite 
these being well established as consequences of poor 
longer-term glycaemic control.22 A comparative effec-
tiveness pragmatic clinical trial, the Glycemia Reduction 
Approaches in Diabetes, is underway that will compare 
sitagliptin with sulfonylureas in individuals with T2DM 
inadequately controlled on metformin for longer-term 
complications.57 However, the results of this trial are not 
expected until 2020, and this evidence is needed urgently. 
Mounting observational data could help investigate these 
outcomes.
strengths and limitations
Our study has some important strengths. This is the first 
systematic review, to our knowledge, to assess effectiveness 
from both RCTs and non-randomised studies comparing 
sitagliptin with sulfonylureas as add-on to metformin. 
Secondly, we have reported data across a wide range of 
outcomes, and thirdly, we have undertaken meta-analysis 
only where methodologically appropriate in accordance 
with our prespecified protocol.21
There are also some limitations to acknowledge. 
Firstly, we have focused entirely on effectiveness in this 
review because safety has been evaluated in-depth else-
where as summarised earlier.8 11 12 15 58Secondly, we have 
presented intention-to-treat results (where available) from 
each study reported. Though this can bias results towards 
equivalence if there are high dropout rates or consid-
erable switching in studies, this was not the case across 
studies included. Moreover, our goal was to shed further 
light on the effectiveness of sitagliptin compared to sulfo-
nylureas with a focus on the initial prescribing decision, 
and this was the most informative approach to achieve this. 
Thirdly, our analysis has focused on sitagliptin only as it 
has been the most extensively prescribed DPP-4 inhibitor 
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in the UK and USA.7 Different sulfonylureas do exhibit 
different pharmacokinetic behaviour, particularly with 
regards to duration of action; however, they have been 
grouped together because included studies used mainly 
newer generation sulfonylureas, which from a pharma-
codynamic effectiveness point of view, behave similarly.43 
Finally, despite high prevalence of type 2 diabetes in Asia, 
no study based solely within an Asian country qualified 
for the meta-analysis. This omission is of significance as 
evidence is emerging that suggests that glycaemic effec-
tiveness of DPP-4 inhibitors like sitagliptin may in fact 
be greater in East Asians. This may be due to phenotypic 
variation in diabetes and highlights why further research 
may be needed to identify Asian ethnic subgroups who 
may need different therapeutic approaches.59
cOnclusIOns
In summary, the absence of data on effectiveness 
comparing sitagliptin with sulfonylureas among individ-
uals with T2DM inadequately controlled on metformin 
for reducing longer-term complications of T2DM means 
treatments decisions for effectiveness (once safety has 
been considered) must be based on short-term to medi-
um-term outcome data available. In this respect, we have 
shown that glycaemic control with both treatments was 
similar. Statistically significant weight reduction of close to 
2 kg was observed with use of sitagliptin when compared 
to sulfonylureas in both RCTs and non-randomised 
studies, though this may not be of major clinical impor-
tance for most individuals. Non-randomised studies also 
reported that there was a lower likelihood of treatment 
change after initiation of sitagliptin compared to sulfo-
nylureas. However, it was difficult to interpret if this was 
necessarily a positive finding due to lack of glycaemic data 
at time of treatment change. Further comparative effec-
tiveness research work is needed from RCTs or non-ran-
domised studies to address evidence gaps relating to risks 
of longer-term macrovascular and microvascular compli-
cations of T2DM.
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